Clinical Trial Goal
To find out:
- The highest dose of BMS-986497 that's safe to give
- If BMS-986497, alone or with azacitidine and venetoclax, is safe and works well to treat AML or MDS that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years or older
- Have AML or MDS that has relapsed or is refractory
- Have cancer cells with marker CD33 (CD33+). Your doctor can tell you this
- Do not have acute promyelocytic leukemia
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Azacitidine is a drug that blocks the growth of cancer cells.
BMS-986497 is a protein degrader that targets CD33 and GSPT1 on certain cells.
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
In this trial, you’ll be placed in 1 of 2 groups:
BMS-986497 is a protein degrader that targets CD33 and GSPT1 on certain cells.
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
In this trial, you’ll be placed in 1 of 2 groups:
- Group 1 – BMS-986497
- Group 2 – BMS-986497 plus azacitidine
- Group 3 - BMS-986497 plus azacitidine and venetoclax
You’ll get:
- Azacitidine - Group 2 and 3 only - Given as intravenous (IV) infusions
- BMS-986497 – Given as IV infusions. The dose you'll get depends on when you start the trial and how safe it has been
- Venetoclax - Group 3 only - A pill that you take by mouth
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 4 years.
The Food and Drug Administration (FDA) has not yet approved BMS-986497.
Contacts
BMS Study Connect Contact Center www.BMSStudyConnect.com, 855-907-3286, Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Locations
Sponsors
lead: Bristol-Myers Squibb
